Literature DB >> 16200602

Similar cell surface expression of beta2-microglobulin-free heavy chains by HLA-B27 subtypes differentially associated with ankylosing spondylitis.

Miriam N Vázquez1, José A López de Castro.   

Abstract

OBJECTIVE: To determine whether the cell surface features of HLA-B27 subtypes reported to be differentially associated with ankylosing spondylitis (AS) differ in a way that correlates with disease susceptibility.
METHODS: Human cell transfectants expressing or lacking the transporter associated with antigen processing were used to determine the cell surface expression of B27 subtypes by flow cytometry with antibodies recognizing the B27 heterodimer or beta2-microglobulin (beta2m)-free heavy chains.
RESULTS: In lymphoid cells with an intact peptide-loading complex, all B27 subtypes, irrespective of their association with disease, showed similar ratios of free heavy chain to heterodimer, suggesting similar surface stability. A substantial decrease in dissociated heavy chains, which never reached 100%, was observed upon addition of a B27 ligand, with no significant differences among subtypes. This is compatible with similar surface expression of irreversible beta2m-free heavy chain forms among subtypes differentially associated with disease. In cells lacking the transporter associated with antigen processing, both disease-associated and non-disease-associated subtypes expressed a population of heterodimers at 26 degrees C that was less stable than the population expressed at 37 degrees C. In the presence of exogenous peptide, the expression of heterodimers increased, without a concomitant decrease in beta2m-free heavy chains. This suggests that in these cells, and for all subtypes tested, most of the dissociated heavy chains at the cell surface are in irreversible forms. At 37 degrees C, the expression of beta2m-free B27 heavy chains was very low on T2 transfectant cells.
CONCLUSION: HLA-B27 subtypes showing differential associations with AS are similar in their extent of beta2m dissociation and surface expression of free heavy chains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16200602     DOI: 10.1002/art.21284

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Mutational analysis reveals a complex interplay of peptide binding and multiple biological features of HLA-B27.

Authors:  Begoña Galocha; José A López de Castro
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

2.  Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome.

Authors:  Pablo Guasp; Elena Lorente; Adrian Martín-Esteban; Eilon Barnea; Paolo Romania; Doriana Fruci; JonasJ W Kuiper; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2019-05-15       Impact factor: 5.911

Review 3.  The interplay between HLA-B27 and ERAP1/ERAP2 aminopeptidases: from anti-viral protection to spondyloarthritis.

Authors:  C Vitulano; V Tedeschi; F Paladini; R Sorrentino; M T Fiorillo
Journal:  Clin Exp Immunol       Date:  2017-08-30       Impact factor: 4.330

Review 4.  Ankylosing spondylitis is linked to Klebsiella--the evidence.

Authors:  Taha Rashid; Alan Ebringer
Journal:  Clin Rheumatol       Date:  2006-12-21       Impact factor: 3.650

5.  A common minimal motif for the ligands of HLA-B*27 class I molecules.

Authors:  Alejandro Barriga; Elena Lorente; Carolina Johnstone; Carmen Mir; Margarita del Val; Daniel López
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

6.  CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection.

Authors:  Jing Wei; Jing Peng; Bing Wang; Hong Qu; Shiyi Wang; Aziz Faisal; Jia-Wei Cheng; John R Gordon; Fang Li
Journal:  Biomed Res Int       Date:  2013-03-18       Impact factor: 3.411

7.  Ankylosing spondylitis: from cells to genes.

Authors:  José Francisco Zambrano-Zaragoza; Juan Manuel Agraz-Cibrian; Christian González-Reyes; Ma de Jesús Durán-Avelar; Norberto Vibanco-Pérez
Journal:  Int J Inflam       Date:  2013-07-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.